人民同泰：股票交易风险提示公告

Group 1 - The company, Renmin Tongtai, announced that as of November 11, 2025, its rolling price-to-earnings (P/E) ratio is 55.29, which is significantly higher than the industry average [2] - The "pharmaceutical commerce" industry has a rolling P/E ratio of 18.43, indicating that the company's valuation is notably elevated compared to its peers [2] - Investors are advised to be cautious of trading risks in the secondary market and to make rational investment decisions [2]